Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0UYFKW
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
vBC101-F11
|
|||||
| Synonyms |
VBC101-F11; VBC101
Click to Show/Hide
|
|||||
| Organization |
VelaVigo (Originator)
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
|
|
||||||
| Antibody Name |
Anti-EGFR/c-Met bsAb
|
Antibody Info | Antigen Name | |||
| Payload Name |
MMAE
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Undisclosed
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Unspecific solid tumor |
1 Trials
|